Audited Financial Results for the year ended 31.03.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.0 pts less than Nifty Microcap 250 and 7.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Gujarat Terce Laboratories reported FY25 revenue from operations of ₹5,019.52 lakhs, up about 4.6% from ₹4,797.47 lakhs in FY24. Q4 FY25 revenue was ₹1,232.44 lakhs, nearly flat versus ₹1,220.71 lakhs in Q4 FY24. Profit before tax jumped sharply to ₹339.04 lakhs from ₹54.39 lakhs, but this includes a one-time charge of ₹341.71 lakhs related to disputed income-tax of earlier years (FY2010-11 to FY2013-14) settled under the Direct Tax Vivaad se Vishwas scheme. After this charge, net profit for FY25 came in at ₹97.87 lakhs versus ₹24.34 lakhs in FY24, with basic EPS of ₹1.31 (vs ₹0.33). Operating cash flow improved to ₹305.91 lakhs from ₹259.97 lakhs. Auditor M.A. Shah & Co. issued an unmodified (clean) opinion and confirmed no going-concern issues.
Headline PAT growth looks strong (roughly 4x), but a large one-time tax provision masks underlying profitability; adjusted profits would be significantly higher. Other equity remains in negative territory (₹-129.28 lakhs) and short-term provisions surged to ₹708.79 lakhs (from ₹310.93 lakhs) due to the tax settlement. Stock may see muted reaction given the modest revenue growth and the noise from the one-time tax item.